close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

248.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
News headline image
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗
Drug pricing matters, but pipelines matter even more. 
Via The Motley Fool
Topics Government Intellectual Property
News headline image
3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors ↗
You need to look beyond the tech sector to find great dividend stocks for the long term. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗
AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak. 
Via The Motley Fool
Topics Intellectual Property
Cannabis Theme Rally Powered by Profitability, Not Pure-Play Speculation ↗
Via Chartmill
Topics Cannabis
News headline image
5 Dividend Kings to Buy in July with Irristable Value and Yield ↗
Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds. 
Via MarketBeat
News headline image
3 Reasons to Buy Novo Nordisk Stock ↗
The stock is down, but it isn't out yet. 
Via The Motley Fool
News headline image
U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗
Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks. 
Via The Motley Fool
News headline image
Abivax: Wall Street Catches Up to the Data ↗
Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional... 
Via MarketBeat
News headline image
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) ↗
It doesn't get much more dependable and lucrative than the healthcare industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dividend ETF Quietly Outperforming the S&P 500 ↗
This dividend ETF's focus beyond yield continues to pay off for investors. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Is Apple Stock a Buy After Its Recent Pullback? Here's What History Suggests. ↗
Look for history to repeat itself with Apple's latest pullback. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Market-Beating Stocks Worth Investigating
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway. ↗
Via Chartmill
News headline image
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
News headline image
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today ↗
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.03% on an annualized basis producing an average annual return of 16.59%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
News headline image
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗
AbbVie knows how to plan ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now ↗
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? ↗
In the past five years, this top healthcare stock has risen by close to 130%. 
Via The Motley Fool
News headline image
2 S&P 500 Stocks with Promising Prospects and 1 We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Retirement Stocks
News headline image
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is AbbVie a Buy After Its Purchase of Apogee? ↗
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion? 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years ↗
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis producing an average annual return of 15.79%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
News headline image
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
These healthcare stocks may be the building blocks of a winning portfolio. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why AbbVie Stock Jumped Today ↗
An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline. 
Via The Motley Fool
News headline image
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗
The company is already renowned by many as a giant in the segment. 
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
5 Dividend Stocks to Buy and Hold Forever ↗
Get rich slowly. How? Hold these stocks and reinvest the dividends they pay. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Excellent Dividend Stocks to Buy on the Dip ↗
Don't wait too long to get in on these outstanding dividend payers. 
Via The Motley Fool
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.